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Introduction
Rubella is an exanthematic disease which is generally 
mild but can have potentially dramatic consequences for 
the foetus if contracted during pregnancy. The rubella 
virus can transplacentally infect the product of concep-
tion. Indeed, 85% of infections contracted in the first 
trimester of pregnancy can cause spontaneous abortion, 
intrauterine death or extremely serious foetal malforma-
tions, such as deafness, mental retardation, cataracts and 
other eye diseases, heart defects, etc. (congenital rubella 
syndrome - CRS). 
The main aim, therefore, of rubella vaccination pro-
grammes is to prevent pregnant women from becom-
ing infected and, consequently, to prevent congenital 
rubella (CR).
In Italy, the rubella vaccine was introduced in 1972 and 
initially vaccination was recommended only for prepu-
bertal girls. Currently, the national vaccination calendar 
provides for immunisation using the combined measles-
mumps-rubella vaccine (MMR) for all newborn babies 
aged 12-15 months. In addition catch-up initiatives are 
organised under the National Elimination Plan for Mea-
sles and Congenital Rubella (PNEM) [1].
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The medium-term targets set by the PNEM, regard-
ing vaccination coverage for an MMR dose by the age 
of two years old, are to achieve and maintain, at both 
national and regional level, 85% coverage by 2004 and 
90% by 2005. By 2006 the target is 95% coverage of at 
least one dose of MMR in children aged between 3 and 
15 years. Routine statistics for the year 2005 show the 
national average to be 89% (range: 58-93%) [2]. Eight 
regions achieved the 90% target, while ten regions 
managed 85-89% coverage and three fell below 85%, 
including the region of Sicily with a vaccination cover-
age rate of 81%. 
Although the national vaccine coverage rate achieved 
for newborns [3] has reduced the virus in circulation, it 
has not eradicated it. Thus, there still remains a signifi-
cant risk of CR in Italy, where high levels of susceptibil-
ity to rubella exist in both the general population as well 
as in women of childbearing age. In the first half of the 
year 2008, point epidemics of rubella were recorded in 
the Italian regions of Friuli-Venezia Giulia, Piemonte 
and Calabria, with a parallel increase of cases occurring 
in pregnancy [4]. These outbreaks demonstrate the need 
to identify and recoup those women of childbearing age 
who are still at risk.
Summary
Introduction. Rubella	can	have	particularly	 serious	effects	on	
the	product	of	conception	if	contracted	during	pregnancy.	Thus,	
the	main	aim	of	 rubella	 vaccination	programmes	 is	 to	prevent	
infection	during	pregnancy.
Materials and methods. A	 seroepidemiological	 study	 was	
conducted from	July	2006	 to	December	2007	on	1,000	women	
of	childbearing	age,	15	to	45	years	old,	using	specific	rubivirus	
antibody	 assays,	 IgG	 and	 IgM.	 A	 questionnaire	 administered	
at	 the	 same	 time	allowed	us	 to	 survey	how	much	women	knew	
about	 this	 disease.	 In	 addition,	 MMR	 vaccine	 coverage	 rates	
were	 analysed	 for	 cohorts	 born	 in	 the	 local	 health	 districts	 of	
Messina	for	the	period	1993-2006.
Results. An	 analysis	 of	 the	 replies	 given	 to	 the	 questionnaire	
showed	 an	 estimated	 42.8%	 of	 the	 women	 to	 have	 immunity	
from	 rubella,	while	 the	 serological	 study	 showed	 an	 immunity	
coverage	rate	of	80.6%.	Vaccination	coverage	in	the	local	health	
districts	 regarding	 the	 first	 dose	 of	 MMR	 was	 81%	 (cohorts	
1993-2005),	while	 the	 rate	was	 only	 24%	 for	 the	 second	 dose	
(cohorts	1993-2002).
Conclusions. Both	 immunity	 coverage	 in	women	 of	 childbearing	
age	and	that	for	newborns	(for	the	cohort	considered)	fall	below	the	
95%	target	set	by	the	National	Elimination	Plan	for	Measles	and	
Congenital	Rubella	 (PNEM).	 It	 is	 therefore	 necessary	 to	 provide	
women	with	adequate	 information	about	 the	risks	of	 rubella	dur-
ing	pregnancy	and	about	the	benefits	of	vaccination,	as	well	as	to	
recoup	subjects	at	risk	or	those	whose	immune	status	is	unknown.	
Public	 health	 authorities	 also	 need	 to	 make	 continued	 efforts	 to	
increase	the	number	of	MMR	vaccinations	throughout	the	region.
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It has been estimated that to prevent CRS the percentage 
of susceptible women of fertile age must not exceed 5%, 
but the few studies of seroprevalence available show 
that the actual percentage still falls far short of national 
targets. In order to redress this shortfall, PNEM initia-
tives are designed to achieve and maintain over time a 
high rate of vaccination coverage in paediatric age and 
to assess the immunity of women of fertile age in order 
to vaccinate those susceptible prior to any pregnancy.
A seroepidemiological study was carried out in order to 
add to the current knowledge base regarding the avail-
able national statistics. The study was conducted on a 
female population of childbearing age and also assessed 
MMR vaccine coverage for cohorts born in the period 
1993-2006 in the Italian city and province of Messina. 
Moreover, given the unsatisfactory results so far ob-
tained from the initiatives targeting women of child-
bearing age, a questionnaire was also given to the same 
sample of subjects. The aim was to study the level of 
knowledge and awareness of the potential dangers of 
rubella contracted during pregnancy.
Materials and methods
The study was carried out from July 2006 to December 
2007 on a total of 1,000 women aged between 15 and 45 
years who were resident in the province of Messina.
Having obtained their informed consent, a blood sample 
was taken from each woman to assay the anti-rubella 
antibodies IgG and IgM. The samples were taken at the 
University hospital in Messina (AoU “G. Martino”) at 
the outpatient clinic and at our facility. Commercial kits 
were used to assay the antibodies, i.e. AxSYM Rubella 
IgG and Rubella IgM (ABBoTT Diagnostics Division), 
using the Microparticle Enzyme Immunoassay (MEIA). 
on the basis of assay criteria, the results equal to or 
greater than 10 UI/ml were considered positive for IgG 
anti-rubella antibodies, while samples with an index 
equal to or greater than 0.800 were considered positive 
for IgM anti-rubella antibodies. 
Each woman who took part in the study was given a 
questionnaire (Fig. 1) to collect their demographic data, 
including level of education. The questionnaire also in-
Fig. 1. Questionnaire used.
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cluded a series of questions designed to obtain informa-
tion about subjects’ level of knowledge about the risks 
of rubella in pregnancy, about any prior history of the 
disease and vaccinations received. 
The women recruited to take part in this study were 
divided into three age-groups as follows: 15-25, 26-35, 
36-45 years.
The replies to the questionnaire were assessed using the 
software Epi Info 6.04d (Centers for Disease Control 
and Prevention – Atlanta - USA).
Administrative data held by the local health unit 5 (ASL) 
of Messina were used to assess MMR vaccine coverage 
in cohorts born between 1993-2006. Local health unit 
5 comprises the following eight Health Districts that 
cover all of the 108 local council areas that make up the 
entire Province: Messina, Taormina, Milazzo, Lipari, 
Barcellona, Patti, Mistretta and S. Agata Militello.
Results
The analysis of the replies to the questionnaire showed 
that 646 of the women interviewed (65% of the sample) 
were aware of the harm that rubella may cause a foetus if 
the disease is contracted during pregnancy. As shown in 
Figure 2, the main source of this information (55%) came 
from subject’s own studies, 19% came from a G.P. (Ge-
neral Practitioners) and only 4% from a gynaecologist.
The majority of the women interviewed had a medium-
high level of education, 21% held a university degree, 
55% a higher secondary school leaving diploma, 22% 
held a lower secondary school diploma and 2% a pri-
mary school leaving certificate (Fig. 3).
on the basis of the answers given to certain items in 
the questionnaire, the estimated number of women that 
declared being immune to rubella was 428 (42.8%); 
while 326 (32.6%) stated that they had already had the 
disease and 102 (10.2%) said they had been vaccinated 
in the past. As regards the latter, 17 women (16.7%) 
declared having been vaccinated at secondary school, 9 
(8.8%) prior to a pregnancy and 31 (30.4%) postpartum, 
while the remaining 45 women (44.1%) were unable to 
indicate when they had been vaccinated.
However, the serological tests showed the actual immu-
ne coverage of the population studied to be 80.6% (Fig. 
4). Indeed, 806 of the 1000 sera samples examined, 
presented specific IgG anti-rubella antibodies while 194 
were negative. No positive cases of IgM were found. 
Table I shows the results by age group. The highest im-
mune coverage (41.2%) was found in the 15-25 year-old 
group followed by 33.5% in the group aged 26-35 years 
and, finally, 25.3% for the group aged 36-45 years.
As regards the IgG concentrations for the individual 
samples, the geometric mean of antibody titres was 
128.23 UI/ml in 15-25 year-olds, 119 UI/ml in the 26-35 
age group and 117.24 UI/ml in 36-45 year-olds.
The women that were found to be susceptible were en-
couraged to have an anti-rubella vaccination and were 
Fig. 2. Sources of information.
Fig. 3. educational level of population sample studied.
Fig. 4. immunity status of population sample studied.
Tab. I. immunity status analysed by age-group.
Age 15-25 26-35 36-45 Total
immune 332
(41.2%)
270
(33.5%)
204
(25.3%)
806
Susceptible 78
(40.2%)
52
(26.8%)
64
(33%)
194
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offered this free of charge. This enabled us to vaccinate 
62 (32%) of the non immune women at our facility.
Administrative data regarding MMR vaccination cove-
rage in the province of Messina, for all health districts in 
the province, was updated to 31 october 2008. The data 
were complete for cohorts born in the years 1993-2005 
but only partially complete for cohorts born in 2006. 
Vaccination coverage for the ASL 5 Local Health Au-
thority district regarding the first dose of MMR was 81% 
for 1993-2005 cohorts (Tab. II), while the second dose 
covered only 24% of 1993-2002 cohorts (Tab. V).
Table III shows the percentage of vaccination covera-
ge achieved by MMR dose analysed by year of birth 
and for each individual health district. What strongly 
emerges is how widely coverage varies from district to 
district, from 10% for year of birth 1993 in the district 
of Lipari up to 99% for the years 1998 and 1999 in the 
district of Patti, a level also achieved in Messina but 
only for the year 2001. Furthermore, an increase can be 
seen in almost all districts up to 2001. However, in su-
bsequent years a decrease in coverage was seen in more 
than half of these districts. 
Table IV reports the partial data for the first dose of 
MMR for cohorts born in 2006, updated to 31 october 
2008. 
Table V reports the percentage of vaccination covera-
ge achieved for the entire ASL 5 area for cohorts born 
between 1993-2002, with the first dose of MMR vaccine. 
It also shows the percentage vaccinated with the 2nd dose 
but this is updated to 31 December 2007. It can be seen 
from the Table that a coverage rate of over 85% for the 
first dose of MMR was achieved in the province of Mes-
sina only for the years 1998-99 and 2001-02 with a sharp 
increase in 2001 up to 95%, while the average percentage 
for the second dose was 24% with peak levels of 32% and 
38% being achieved in the years 1998-99 respectively. 
Discussion and conclusions
An analysis of the results prompts the following consi-
derations.
35% of the women who took part in the study did not 
know of the damage that the rubella virus can cause to the 
foetus during pregnancy and of those who were aware of 
the risks only 4% reported that this information had come 
from a gynaecologist, 19% from a G.P. while the majority 
55% had learned through their own studies. The latter is 
correlated with the high educational level of the subjects 
in our study (Pearson correlation coefficient = 0.657). 
Interestingly, education influences only awareness of 
the risks but not the decision to be vaccinated. Indeed, 
there was no significant statistical difference between 
women who had been vaccinated and those who repor-
ted not having done so (p > 0.05), in relation to both 
educational level as well as the source of information 
about risks.
The results reported in Table I highlight how the per-
centage of immune women falls as age increases. When 
considering the overall immunity status (immune/non 
immune) by age-group there is a statistically significant 
difference only between the 26-35 age-group and 36-45 
year-olds (p < 0.05).
Tab. II. mmr vaccine coverage for entire ASL 5 local health authority area.
Year of birth 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Mean
(%)
ASL 5
(%) 62 71 71 75 85 88 87 82 95 87 87 86 82 81
Tab. III. mmr vaccine coverage: first dose by year of birth and health district.
Year of birth 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Mean
 (%)
messina 54 62 66 70 82 87 84 82 99 93 87 81 77 79
taormina 56 62 64 58 70 74 73 72 89 89 82 80 90 74
milazzo 82 87 83 82 93 93 93 87 91 87 93 90 90 89
Lipari 10 40 47 49 43 47 79 68 97 83 79 45 48 57
barcellona 69 78 72 83 87 81 83 81 91 83 92 77 79 81
patti 63 84 83 93 97 99 99 77 84 70 78 68 72 82
mistretta 61 82 67 82 90 91 89 56 97 93 89 90 98 83
S.Agata m. 73 73 71 74 83 88 90 86 89 81 86 81 47 79
n.b.: data refer to cohorts aged 24 months
Tab. IV. mmr vaccine coverage: first dose partilal data. 
Year of birth 2006
messina 71
taormina 59
milazzo 91
Lipari 50
barcellona 74
patti 89
mistretta 99
S. Agata m. 73
media (%) 76
n.b.: data refer to cohorts aged 24 months
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17.5% of the women who reported knowing the risks 
of rubella in pregnancy were not protected from those 
same risks and from checks on the vaccination status it 
emerged that 9.8% of the women who reported having 
been vaccinated did not have protective antibodies. This 
is probably due to the inadequacy of information given 
to the target population which led to confusion regar-
ding the vaccinations given. 
only 42.8% of the population examined knew that they 
were immune to rubella while a high percentage (30%) 
of women were unaware of their own immune status. 
The offer of a free anti-rubella vaccine allowed us to 
claw back only 32% of the women at risk. Indeed, re-
sistance to the proposed vaccination was encountered 
in people who had not been immunised which is attri-
butable more to unresolved doubts rather than to any 
concrete reasons. 
The immunity coverage of the population examined of 
80.6% falls far short of the 95% target set by the National 
Elimination Plan for Measles and Congenital Rubella. 
Based on administrative data, even the vaccination co-
verage rates achieved for newborns are lower than the 
PNEM targets set for the year 2005. The high vaccination 
coverage rates that were achieved in some districts up 
until 2002 can be traced to initiatives organised by the Si-
cilian Regional Authority which in 1998 strengthened the 
supply of MMR vaccinations [5]. Moreover, in the year 
2000 it launched a regional project to prevent measles, 
mumps and rubella [6] which aimed to recoup people 
born between 1993 and 1999 who had not been vaccina-
ted, and in 2004 it set up a catch-up MMR vaccination 
programme [7] which implemented a more effective 
MMR recruitment strategy for newborns and for the sup-
ply of a second dose of MMR at the age of 5 years old.
However, as normally happens once a special campaign 
comes to an end, the numbers accessing the vaccination 
programme subsequently diminished. This highlights that 
MMR vaccination requires a continued and constant effort 
by the public health system to cover the entire region.
A further point based on the above considerations is 
that women clearly need to be informed adequately and 
continuously about the risks of rubella in pregnancy as 
well as about the benefits of being vaccinated and that 
steps need to be taken to recoup susceptible women or 
women whose immune status is unknown.
It is vitally important, therefore, that all healthcare 
workers (G.Ps, gynaecologists, paediatricians, obstetri-
cians) are involved and collaborate in this process. It 
is also important to provide informative material and 
use various means of communication to promote such 
an initiative. The final goal is to reduce the number of 
susceptible women of childbearing age to below 5%, the 
threshold set by the National Programme which is indis-
pensable for congenital rubella to be eradicated.
Tab. V. mmr vaccine coverage first and second dose. 
Year of birth 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Total
n. born for year 7202 6725 6396 6212 5888 5702 5597 5736 5515 5391 60364
n. vaccinated 1st dose 4453 4751 4568 4669 5024 5016 4905 4739 5288 4702 48115
% 1st dose 62 71 71 75 85 88 87 82 95 87 80
n. vaccinated 2nd dose 1558 1752 1583 1479 1474 1841 2137 1601 841 111 14377
% 2nd dose 22 26 25 24 25 32 38 28 15 2 24
n.b.: the number born for year are shown based on information collected by individual councils.
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